This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Bill Nye the Science Guy is back but on an even smaller screen. America’s favorite science teacher has racked up more than eight million followers on TikTok, and he joined Cheddar News to talk about his success on the platform, having fun but also being serious about scientific topics like tackling climate change, and his newest hosting project "The End is Nye," a streaming show on Peacock that examines disasters — both natural and manmade. "There are six episodes. We have big disasters. Things go terribly wrong, and then we show you how things could have gone right," he explained.
You probably have your summer music playlist ready to to go, but you're probably not aware how an in-store shopping soundtrack may impact your experience. Spotify Advertising took a look at how audio affects small business shopping. Rochelle Sanchirico, Global Director of Scaled Business and Marketing at Spotify Advertising, joins Cheddar News to discuss.
Summer travel season is just around the corner, as the U.S. is entering a fifth COVID-19 wave. Cheddar News speaks with Dr. Jen Caudle, Family Physician and Associate Professor at Rowan University on how to evaluate your vacation plans.
Catching you up on what you need to know on Wednesday, June 1, 2022, House lawmakers hold an emergency hearing on gun control measures in the wake of the Uvalde shooting, the Supreme Court temporarily blocks Texas' law stopping social media moderation, and the James Webb Space Telescope gets a new mission.
With the baby formula in the United States surging to an out-of-stock rate of 70 percent, the FDA has given Abbott permission to reopen its Michigan plant amid the crisis and authorized foreign imports. Professor Peter Pitts, a former FDA associate commissioner and current president of the Center for Medicine in the Public Interest, joined Cheddar News to discuss the ongoing shortage and its wide impact. “As difficult as things is in urban areas, they’re even worse in small communities and tribal areas where parents can't just go to the next store on the corner," he said. Pitts also noted that the Abbott factory was a "disaster" prior to its shutdown and that it would have been "regulatory malpractice" to have left it open.
Scientists are hoping that the simplest element in the universe — hydrogen — can be the solution to slowing down climate change. However, it does not come without cost. The process of making hydrogen could potentially add more CO2.
Pfizer said it will be shipping its vaccines at not-for-profit prices to 45 low-income countries. The pharmaceutical giant will be exporting 23 drugs, including those that treat cancer, heart conditions, autoimmune diseases, as well as COVID-19.
It's not a scene from a movie: an asteroid the size of Mount Everest is headed toward earth. It's bigger than 99% of the asteroids in our solar system. But Cheddar anchor Shannon Lanier says fear not. The giant rock will miss us by more than 2 million miles.
